142 results match your criteria: "Samsung Medical Center Sungkyunkwan University School of Medicine[Affiliation]"

Purpose: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13), in patients with R/R PTCL.

Patients And Methods: Patients included those with CD30 expression in ≥1% of tumor cells and who were R/R following ≥1 prior line of systemic therapy.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to determine if analyzing multiple ECGs over time could better predict new-onset atrial fibrillation (AF) compared to looking at a single ECG.
  • Researchers developed and compared two machine learning models (single ECG vs. serial ECG) using data from over 415,000 ECGs of nearly 176,000 patients.
  • The results showed the serial ECG model significantly outperformed the single ECG model in predicting AF, with improvements in sensitivity, specificity, accuracy, and other performance metrics; key ECG parameters like P-wave duration and amplitude were important for future AF prediction.
View Article and Find Full Text PDF
Article Synopsis
  • FGFR genomic alterations are found in 5-10% of human cancers, and erdafitinib has shown promise in treating various advanced solid tumors but its effectiveness in Asian patients was unclear.
  • A phase IIa study was conducted to assess the efficacy of erdafitinib in Asian patients with FGFR-altered advanced cholangiocarcinoma, non-small cell lung cancer (NSCLC), and esophageal cancer by evaluating various response rates and survival metrics.
  • Results indicated a 40.9% objective response rate in cholangiocarcinoma patients, while NSCLC did not show any objective responses; however, all patients experienced adverse effects, highlighting the need for further safety assessment.
View Article and Find Full Text PDF

Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.

Cancer Immunol Immunother

August 2024

Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-Ro, Bundang-Gu, Seongnam, 13620, Republic of Korea.

Article Synopsis
  • The study investigates potential biomarkers to predict how breast cancer patients might respond to a combination of immunotherapy and chemotherapy, focusing on tumor samples from the KORNELIA trial.
  • Researchers analyzed genomic and transcriptomic data to differentiate between patients who had good progression-free survival (PFS) and those who did not, looking at factors like tumor mutation burden (TMB) and TP53 mutations.
  • Findings suggest that higher TMB and specific immune cell profiles correlate with better treatment outcomes, offering insights for future research on treatment combinations and biomarkers in HER-2-negative metastatic breast cancer.
View Article and Find Full Text PDF

Background: Although peripartum cardiomyopathy (PPCM) is a fatal disease affecting young patients and fetuses, little is known about its recent prognosis and risk factors. This study investigated temporal trends in clinical characteristics and outcomes for PPCM in a nationwide multicenter registry.

Methods And Results: The study population comprised 340 patients (mean age, 33 years) who were diagnosed with PPCM between January 2000 and September 2022 in 26 tertiary hospitals in South Korea.

View Article and Find Full Text PDF

Background: This cohort study aims to examine the relationship between the occurrence of cranial nerve palsy (CNP) affecting the third, fourth, or sixth cranial nerve and the subsequent risk of stroke, with a particular focus on the modulating effect of age on this association.

Methods And Results: We established a cohort of individuals diagnosed with third, fourth, or sixth CNP who underwent national health screening within 2 years of diagnosis from 2010 to 2017. A control group was matched by sex and age at a ratio of 1:5.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the impact of genetic variations on clinical outcomes in older patients (≥75 years) undergoing percutaneous coronary intervention (PCI) with clopidogrel-based therapy.
  • Patients were categorized into normal, intermediate, and poor metabolizers based on their genotypes, revealing significant differences in 3-year major adverse cardiac events among these groups.
  • The findings indicated that older patients with loss-of-function alleles experienced higher rates of cardiac events and mortality, highlighting the need for tailored antiplatelet strategies in this population.
View Article and Find Full Text PDF

Risk of Heart Disease in Patients With Amputation: A Nationwide Cohort Study in South Korea.

J Am Heart Assoc

May 2024

Department of Clinical Research Design & Evaluation Samsung Advanced Institute for Health Science & Technology (SAIHST), Sungkyunkwan University Seoul Republic of Korea.

Background: Amputation confers disabilities upon patients and is linked to substantial morbidity and death attributed to heart disease. While some studies have focused on traumatic amputees in veterans, few studies have focused on traumatic amputees within the general population. Therefore, the present study aimed to assess the risk of heart disease in patients with traumatic amputation with disability within the general population using a large-scale nationwide population-based cohort.

View Article and Find Full Text PDF
Article Synopsis
  • Aortic stenosis (AS) is common in older adults and more patients will need noncardiac surgeries, yet research on complications specifically in asymptomatic significant AS patients is limited.
  • A study analyzed 221 patients with asymptomatic significant AS and found no significant difference in major cardiovascular events compared to a control group undergoing similar surgeries.
  • Advanced cardiac damage stage in patients with significant AS emerged as a crucial factor influencing the risk of complications during noncardiac surgery.
View Article and Find Full Text PDF

Background: Although age and body mass index (BMI) significantly affect platelet reactivity units and clinical outcomes after percutaneous coronary intervention, there are limited data on the relationship between high on-treatment platelet reactivity (HPR) and clinical outcomes on age and BMI differences. Thus, we investigated the association of HPR with clinical outcomes according to age and BMI.

Methods And Results: The study analyzed 11 714 patients who underwent platelet function tests after percutaneous coronary intervention.

View Article and Find Full Text PDF
Article Synopsis
  • Surgery combined with chemotherapy is the standard treatment for locally advanced gastric cancer (GC) and gastroesophageal junction cancer (GEJC), but outcomes are often poor, especially in specific genetic subtypes like dMMR/MSI-high.* -
  • Analysis from several clinical trials shows that patients with MSI-high tumors generally have better survival rates than those with MSS/MSI-low tumors, and that female patients with MSS/MSI-low tumors tend to live longer than their male counterparts.* -
  • The study emphasizes that sex can influence the effectiveness of treatments for both MSI-high and MSS/MSI-low non-metastatic GC/GEJC, with surprisingly higher chemotherapy risks noted in females with MSI-high cancers.*
View Article and Find Full Text PDF

Background: TRI-SCORE was recently developed in Europe as a risk model for predicting in-hospital death after isolated tricuspid valve surgery. We aimed to validate TRI-SCORE in an Asian population and investigate its value for predicting long-term outcomes.

Methods And Results: The TRI-SCORE was calculated for 202 patients (65±11 years, 61% women, 81% functional tricuspid regurgitation) who underwent isolated tricuspid valve surgery for severe tricuspid regurgitation at 2 Korean centers and was based on 8 parameters: age, New York Heart Association class, right-sided heart failure signs, furosemide daily dose, glomerular filtration rate, bilirubin, left ventricular ejection fraction, and moderate/severe right ventricular dysfunction.

View Article and Find Full Text PDF

Increased Risk of Myocardial Infarction, Heart Failure, and Atrial Fibrillation After Spinal Cord Injury.

J Am Coll Cardiol

February 2024

Supportive Care Center/Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Science and Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea. Electronic address:

Article Synopsis
  • - This study investigates the higher incidence of heart diseases, specifically myocardial infarction, heart failure, and atrial fibrillation, in spinal cord injury (SCI) survivors compared to a matched group of non-SCI individuals.
  • - Results indicate that SCI survivors face significantly increased risks for these heart conditions, especially among those with severe disabilities, with cervical and lumbar injuries showing the highest risks.
  • - The findings highlight the urgent need for healthcare providers to focus on heart health in SCI patients, as they are at a notably greater risk for these diseases than the general population.
View Article and Find Full Text PDF

Long-Term Functional Outcome in Patients With Isolated Thalamic Stroke: The KOSCO Study.

J Am Heart Assoc

February 2024

Department of Physical and Rehabilitation Medicine, Center for Prevention and Rehabilitation, Heart Vascular Stroke Institute, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Republic of Korea.

Background: Information on the long-term prognosis in patients with isolated thalamic stroke is sparse. We report the functional outcomes of patients with thalamic stroke up to 24 months from the KOSCO (Korean Stroke Cohort for Functioning and Rehabilitation) study.

Methods And Results: Isolated thalamic stroke was defined as the presence of lesions solely in the thalamus, excluding cases with lesions in other brain parenchyma areas apart from the thalamus, as identified by brain magnetic resonance imaging or computed tomography scans.

View Article and Find Full Text PDF
Article Synopsis
  • The KEYNOTE-522 study found that adding pembrolizumab to neoadjuvant chemotherapy improved pathologic complete response (pCR) and event-free survival (EFS) in early triple-negative breast cancer cases compared to chemotherapy alone.
  • This analysis focused on patients from East/Southeast Asia diagnosed with early-stage, nonmetastatic triple-negative breast cancer, and involved a randomized, double-blind trial design with 1174 participants.
  • Patients received either pembrolizumab or a placebo alongside chemotherapy before surgery, with the study's main outcomes being the rates of pCR and EFS after treatment.
View Article and Find Full Text PDF

Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16).

Eur J Cancer

December 2023

Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea. Electronic address:

Article Synopsis
  • - The study aimed to assess the safety and effectiveness of nivolumab combined with eribulin for treating metastatic breast cancer (specifically HR+HER2- and triple-negative BC) in Asian patients, enrolling 90 participants from 10 hospitals in Korea.
  • - Results showed that the six-month progression-free survival (PFS) rates were 47.2% for HR+HER2- patients and 25.1% for those with TNBC, with overall response rates at 53.3% and 28.9%, respectively.
  • - Common side effects included neutropenia and some immune-related adverse events, but the combination therapy indicated promising efficacy, suggesting potential benefits for further cancer treatments.
View Article and Find Full Text PDF

A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.

Cancer Res Commun

September 2023

Early Drug Development Unit, Clinical Research Program, Vall d'Hebron University Hospital and Institute of Oncology (VHIO) and Medical Oncology, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain.

Purpose: CB-103 selectively inhibits the CSL-NICD (Notch intracellular domain) interaction leading to transcriptional downregulation of oncogenic Notch pathway activation. This dose-escalation/expansion study aimed to determine safety, pharmacokinetics, and preliminary antitumor activity.

Experimental Design: Patients ≥18 years of age with selected advanced solid tumors [namely, adenoid cystic carcinoma (ACC)] and hematologic malignancies were eligible.

View Article and Find Full Text PDF
Article Synopsis
  • Metal chelator-based contrast agents are being developed for better cancer diagnosis, but existing options require high doses due to rapid clearance and safety concerns.
  • An innovative enzyme-responsive metal delivery system, Gd@ErMC, selectively targets tumors by releasing gadolinium (Gd) in response to enzymes overexpressed in the tumor microenvironment.
  • Studies in tumor-bearing mice demonstrated that Gd@ErMC has a longer half-life, enhances specificity for tumor detection, and shows safety in histological and serological analyses, making it a promising theranostic agent for MR-guided radiotherapy.
View Article and Find Full Text PDF

KRAS is the most commonly mutated oncogene in advanced, non-squamous, non-small cell lung cancer (NSCLC) in Western countries. Of the various KRAS mutants, KRAS G12C is the most common variant (~40%), representing 10-13% of advanced non-squamous NSCLC. Recent regulatory approvals of the KRAS-selective inhibitors sotorasib and adagrasib for patients with advanced or metastatic NSCLC harboring KRASG12C have transformed KRAS into a druggable target.

View Article and Find Full Text PDF

Background: REGATTA trial failed to demonstrate the survival benefit of reduction gastrectomy in patients with advanced gastric cancer with a single non-curable factor. However, a significant interaction was found between the treatment effect and tumor location in the subset analysis. Additionally, the treatment effect appeared to be different between Japan and Korea.

View Article and Find Full Text PDF

Background Although it is well known that the disordered brain provokes cardiac autonomic dysfunction, the detailed location of brain lesions related to cardiac function warrants further investigation. We aimed to elucidate the brain lesions topographically associated with left ventricular (LV) systolic function measured by myocardial strain in patients with acute ischemic stroke without preexisting primary cardiac dysfunction by using support vector regression lesion-symptom mapping. Methods and Results Subjects were those with LV ejection fraction of 50% or more among patients with acute ischemic stroke registered in the Samsung Medical Center stroke registry between 2016 and 2017.

View Article and Find Full Text PDF